British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars
Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone
EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray
The Science Behind Biosimilars
Biosimilars: Still Waiting for Promise to Materialize